Showing results (191-200 of 209) with videos related to
Sort By:
Pageof 21
European Journal of Nuclear Medicine and Molecular Imaging|August 22, 2014
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancerNeeta Pandit-Taskar, Joseph A O'Donoghue, Volkan Beylergil, et al.International Journal of Radiation Oncology, Biology, Physics|December 26, 2025
Enhancing Radiotherapy Quality Assurance in Lymphoma: A Rigorous Real-Time Central Review Process in AHOD2131Andrea C Lo, Sarah A Milgrom, Raymond Mailhot Vega, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2015
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate CancerNeeta Pandit-Taskar, Joseph A O'Donoghue, Jeremy C Durack, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2021
High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and ParagangliomaAbhishek Jha, David Taïeb, Jorge A Carrasquillo, et al.Academic Radiology|June 20, 2020
Preserving Radiology Resident Education During the COVID-19 Pandemic: The Simulated Daily ReadoutMichael P Recht, Nancy R Fefferman, Mark E Bittman, et al.Blood|September 7, 2017
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphomaAlison J Moskowitz, Heiko Schöder, Somali Gavane, et al.Cancer Chemotherapy and Pharmacology|January 26, 2017
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)Ghassan K Abou-Alfa, Chia-Jui Yen, Chih-Hung Hsu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2023
Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric CancerSteven B Maron, Walid Chatila, Henry Walch, et al.JCO Oncology Advances|May 7, 2025
ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial ResultsEmily K Slotkin, Audrey Mauguen, Filemon S Dela Cruz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2024
Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AMLBoglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, et al.Pageof 21